Fig. 3
hMSCS alleviate angiogenesis and lymphangiogenesis in the corneal allograft and the graft bed. A Image analysis for original immunofluorescent micrograph. The corneal graft was outlined by dashed circle (up). The processed micrographs show the whole corneal area (middle) and lymphatic vessels perfusion area (down). B Representative immunofluorescent micrographs for LYVE-1 staining (for lymphatic vessels) and CD31 staining (for blood vessels) of the corneas on day 15 posttransplant in the absence or presence of indicated 5 × 105 hMSCs administration. C Quantitation of lymphatic neovessel perfusion area for Fig. 3B (n = 3). D Quantitation of neovessel perfusion area for Fig. 3B (n = 3). E The relative mRNA levels of TSP-1, VEGF-A, VEGF-C and FAS in indicate cell were measured by quantitative real-time PCR; all mRNA levels are expressed relative to GAPDH (n = 3). F The protein expression of TSP-1, VEGF-A, FAS and relevant alpha-tubulin in hMSCs as detected by western blotting. Full-length blots/gels are presented in Additional file 1: Fig. S1. G Quantitation of indicated protein expression for Fig. 4F. (H) The protein expression of VEGF-C secreted by hMSCs as detected with ELISA. Bars in (C–E), (G), (H) represent mean ± SD of triplicate biological replicates. *P < 0.05; **P < 0.01; ns not significant; P values were calculated by unpaired t-test